Susan G. Komen

Komen-funded researchers Dr. Anne Marie McCarthy and Mattia Mahmoud studied how normal breast tissue appears on MRI scans and whether this differs by race. Their work shows that Black women are more likely to have higher background enhancement (BPE)—something that can make it tougher to spot suspicious areas on an MRI. Understanding these differences is an important step toward improving risk prediction and ensuring screening works well for everyone. They recently shared more about the study on the Radiology Podcast https://bit.ly/3Ox1vI0

Everyone who has been diagnosed with breast cancer has some risk of it coming back (or recurring). Understanding your recurrence risk can help you and your doctor make decisions that support your long-term health and quality of life. Learn what affects recurrence risk and reasons to follow up after initial treatment: https://bit.ly/3N594VT

Your voice has power and it only takes a minute to use it. At our Action Center, you can take meaningful action to accelerate breast cancer research, ensure access to care, alleviate burdens for patients, and support people impacted by breast cancer. Make your voice heard today! https://bit.ly/3MH1eBM

Thanks to YOU--our participants, teams, donors, sponsors and volunteers--our Race for the Cure and MORE THAN PINK Walk program ranked #20 for revenue on the 2025 U.S. Top 30 list of peer-to-peer fundraising programs, published by the Peer-to-Peer Professional Forum. We also want to recognize our staff for their dedication and commitment to these events. Our Races and Walks are about bringing our community together for a shared purpose of fueling research, patient support and advocacy. Because ending breast cancer needs all of us.

The ShareForCures Alliance is a collaboration of organizations that ensures more voices are heard, more data is represented and more lives are improved. Learn about more about Komen's partnership with Touch, The Black Breast Cancer Alliance, one of the organizations in the ShareForCures alliance and how they are working to make sure representation in research is not symbolic; showing how it directly impacts how breast cancer is diagnosed, treated and understood. https://bit.ly/4b9gG2K

Reducing breast cancer recurrence risk matters. For people with early HR+/HER2- breast cancer, the risk of recurrence can last up to 10 years after diagnosis. The CATE clinical trial is investigating whether combining ctDNA monitoring with oral SERD elacestrant can help reduce future recurrence in people with early HR+/HER2- breast cancer at a higher risk of metastasis. Learn more about the CATE clinical trial in our blog: https://bit.ly/4aMPiWX

Health equity starts with YOU! Join us for the 2026 Komen Health Equity Revolution Summit — a FREE virtual event that brings together leaders across public health, policy, technology and community care to discuss solutions for ensuring everyone has access to quality breast care. 📆 Thursday, March 5th, 10-3 pm CT Register today: https://bit.ly/46UrBee

We’re thrilled to be named a finalist along with our partner Mohawk Industries in the Best Cause Marketing Category for The 2026 Halo Awards presented by Engage for Good! Winners will be named at the #EFG2026 #HaloAwards, April 21-24 in Palm Springs: https://bit.ly/3Fwj0Q7

Managing treatment side effects is an important part of living with metastatic breast cancer, and you don’t have to navigate it alone. Join us for our next MBC Impact Series virtual session, “Ask a Naturopath: Side Effects Management,” on March 9 at 1 PM CT. Naturopaths Dr. Jenna Bailey and Dr. Erica Joseph will share insights and answer your questions to help you protect your quality of life throughout treatment. Save your spot: https://bit.ly/4b5MwgP

"I use my voice to advocate for women, especially Black women, to trust their bodies and speak up in medical spaces. As long as I have breath, I will continue to live with purpose, faith and hope.” - Lea Read Lea's story: https://bit.ly/4s4uiCb